<DOC>
	<DOCNO>NCT01506453</DOCNO>
	<brief_summary>Neuropathic pain / peripheral neuropathy ( NP/PN ) know painful complication vincristine ( VCR ) therapy ; evidence support best treatment plan pediatric patient limited . Gabapentin frequently use VCR-related NP/PN , variable dose scheduling regimen , vary measure success . The hypothesis study gabapentin reduce severity NP/PN patient receive vincristine treatment ALL Total XVI protocol ( treat `` per TOTXVI protocol '' ) , measure two outcome measure : daily dose morphine use need pain addition either gabapentin placebo , randomize , pain score assess daily .</brief_summary>
	<brief_title>Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>Patients ALL Total XVI ( ( treat `` per TOTXVI protocol '' ) experience NP/PN specific dos vincristine eligible enroll study soon diagnosis NP/PN related VCR establish . The qualifying dose vincristine select fall schedule weekly vincristine dos per Total XVI , 2 additional weekly vincristine dos anticipate accord protocol . Participants randomize receive gabapentin placebo upon enrollment . Morphine available group need pain time study . At time enrollment , daily thereafter completion study drug , data collect pain assessment , daily dose oral morphine use collect . Data regard pain type , quality , location , well treatment use manage pain assess daily basis diagnostic event period follow next two administration VCR treat study drug . Primary Objective : To assess analgesic efficacy gabapentin control VCR-related NP/PN participant ALL , compare morphine daily dose ( mg/kg/day ) use control NP/PN primary rescue regimen gabapentin vs. placebo group . Secondary Objective : To compare pain score gabapentin placebo group record pain score right pain score average previous 24 hour .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Participant enrol Total XVI treat `` per TOTXVI protocol '' Participant 1 year age old Participant symptom NP/PN onset 7 day one follow vincristine dos Â± 3 day : protocol week 1 , week 2 ( induction ) , week 7 ( reinduction I ) , week 17 ( reinduction II ) . Patient expect receive 2 dos vincristine weekly interval outline Total XVI protocol ( treat `` per TOTXVI '' protocol ) study drug ( i.e . know dosage reduction plan missed dos ) . Participant able willing take oral medication . Previous participation study Participant receive gabapentin another indication time diagnosis NP/PN receive gabapentin previously . Pregnancy . Female participant childbearing potential must document negative urine serum pregnancy test result old 7 day . Male patient reproductive potential counsel procreate study . Impaired renal function : decrease eGFR ( &lt; 60ml/min/1.73m^2 estimate revise Schwartz equation ) Participant allergy contraindication either morphine gabapentin therapy . Inability unwillingness research participant legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Vincristine</keyword>
	<keyword>TOTAL XVI Protocol</keyword>
</DOC>